“We are impressed with the study outcomes and performance of Ibex Breast, which were in near perfect concordance with the consensus diagnosis between pathologists. Our team demonstrated that Ibex’s AI technology goes beyond diagnosing cancer and provides accurate insights on the type of invasive carcinomas, the nuclear grading of in situ carcinomas and more. I’m confident that AI will provide benefit to cancer patients across the diagnostic workflow”

“The use of AI in diagnosing prostatic cores made me extremely confident in making correct and reproducible tissue diagnosis by the entire pathology team. AI brings this technology into us, as a second pathologist, and it feels like I have an AI consultant sitting with me and helping in the diagnosis. We have been looking under microscopes for hundreds of years, and by adopting digital pathology and artificial intelligence, we are going into the 21st century, enhancing the quality of care to cancer patients”

“AI provides an additional prospective quality control, that we are looking at the right foci and identify the right areas of cancer. The ability of Ibex’s AI platform, not only to detect small foci of cancer that can be missed, but more interestingly and importantly higher-grade cancers that can be very small, make it a perfect companion for pathologists who are reviewing a lot of diagnostic material or may not have the expertise to analyze this material with that level of confidence.”

“I was the primary investigator in a study that validated the performance of Ibex’s Prostate solution. At the end of the study, the team was most impressed with how well the algorithm preformed, with an area under the curve close to near perfect, not only for the diagnosis cancer but also for other clinically relevant features such as Gleason grading, tumor sizing and detection of perineural invasion”